CR20140432A - Virus de la enfermedad de marek modificado y vacunas elaboradas con el - Google Patents

Virus de la enfermedad de marek modificado y vacunas elaboradas con el

Info

Publication number
CR20140432A
CR20140432A CR20140432A CR20140432A CR20140432A CR 20140432 A CR20140432 A CR 20140432A CR 20140432 A CR20140432 A CR 20140432A CR 20140432 A CR20140432 A CR 20140432A CR 20140432 A CR20140432 A CR 20140432A
Authority
CR
Costa Rica
Prior art keywords
disease
virus
marek
vaccines prepared
modified
Prior art date
Application number
CR20140432A
Other languages
English (en)
Inventor
Joyce Pritchard
Teshome Mebatsion
Michel Bublot
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of CR20140432A publication Critical patent/CR20140432A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Vacuna eficaz para combatir la enfermedad de Marek, que puede elaborarse usando un virus de la enfermedad de Marek (MDV) recombinante de la cepa CVI988, que ha sido transformado con una construcción de ADN exógeno que comprende la secuencia de la repetición terminal larga de un virus de la reticuloendoteliosis.
CR20140432A 2012-03-22 2014-09-19 Virus de la enfermedad de marek modificado y vacunas elaboradas con el CR20140432A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261614142P 2012-03-22 2012-03-22
PCT/US2013/032539 WO2013142377A2 (en) 2012-03-22 2013-03-15 Modified marek's disease virus, and vaccines made therefrom

Publications (1)

Publication Number Publication Date
CR20140432A true CR20140432A (es) 2015-01-09

Family

ID=48045766

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140432A CR20140432A (es) 2012-03-22 2014-09-19 Virus de la enfermedad de marek modificado y vacunas elaboradas con el

Country Status (28)

Country Link
US (3) US20130251737A1 (es)
EP (2) EP3326646A1 (es)
JP (1) JP2015512396A (es)
KR (5) KR102586316B1 (es)
CN (1) CN104602706A (es)
AP (1) AP2014007955A0 (es)
AR (1) AR090472A1 (es)
BR (1) BR112014023398A8 (es)
CA (1) CA2868099C (es)
CR (1) CR20140432A (es)
DO (1) DOP2014000215A (es)
EA (1) EA030866B1 (es)
EC (1) ECSP14023407A (es)
ES (1) ES2663610T3 (es)
GE (1) GEP201706650B (es)
GT (1) GT201400199A (es)
HK (1) HK1255682A1 (es)
IL (1) IL234721B (es)
MA (1) MA37432A1 (es)
MX (1) MX355332B (es)
MY (1) MY169061A (es)
NL (1) NL301087I2 (es)
PE (1) PE20150323A1 (es)
PH (1) PH12014502085A1 (es)
TN (1) TN2014000393A1 (es)
UA (1) UA117345C2 (es)
WO (1) WO2013142377A2 (es)
ZA (1) ZA201406884B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868099C (en) * 2012-03-22 2020-12-15 Merial Limited Modified marek's disease virus, and vaccines made therefrom
CN106397602B (zh) * 2016-08-02 2019-06-18 青岛明勤生物科技有限公司 一种分子佐剂加强型鸡马立克氏病蛋白工程疫苗
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642574A (en) 1970-04-29 1972-02-15 Us Agriculture Method for producing vaccine for immunization of poultry against marek{3 s disease
US4160024A (en) 1978-05-01 1979-07-03 Cornell Research Foundation, Inc. Marek's disease vaccine
NL8401120A (nl) 1984-04-09 1985-11-01 Centraal Diergeneeskundig Inst Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek.
US4895718A (en) 1987-07-10 1990-01-23 The United States Of America, As Represented By The Secretary Of Agriculture Serotype 2 Marek's disease vaccine
US4895717A (en) 1987-07-10 1990-01-23 The United States Of America As Represented By The Secretary Of Agriculture Revertant serotype 1 Marek's disease vaccine
CN1261807A (zh) 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 向横纹肌中转移核酸的改进方法和用于实施该方法的组合
US20050019348A1 (en) 2003-07-21 2005-01-27 Reddy Sanjay M. Marek's disease virus vaccine
CA2868099C (en) * 2012-03-22 2020-12-15 Merial Limited Modified marek's disease virus, and vaccines made therefrom
US9113301B1 (en) 2014-06-13 2015-08-18 Snapchat, Inc. Geo-location based event gallery

Also Published As

Publication number Publication date
MX355332B (es) 2018-04-16
UA117345C2 (uk) 2018-07-25
EA201401044A1 (ru) 2015-01-30
DOP2014000215A (es) 2015-04-15
KR20190100431A (ko) 2019-08-28
KR102586316B1 (ko) 2023-10-06
PE20150323A1 (es) 2015-03-05
HK1255682A1 (en) 2019-08-23
BR112014023398A8 (pt) 2022-08-16
MX2014011388A (es) 2014-10-14
KR20140146136A (ko) 2014-12-24
US11510978B2 (en) 2022-11-29
EP3326646A1 (en) 2018-05-30
US20230310589A1 (en) 2023-10-05
EP2827898A2 (en) 2015-01-28
KR20230028595A (ko) 2023-02-28
CA2868099C (en) 2020-12-15
MA37432A1 (fr) 2016-03-31
AP2014007955A0 (en) 2014-09-30
CA2868099A1 (en) 2013-09-26
US20130251737A1 (en) 2013-09-26
JP2015512396A (ja) 2015-04-27
ES2663610T3 (es) 2018-04-16
NL301087I2 (nl) 2022-03-11
KR20230145532A (ko) 2023-10-17
IL234721B (en) 2018-05-31
MY169061A (en) 2019-02-12
ZA201406884B (en) 2015-11-25
PH12014502085B1 (en) 2014-11-24
GT201400199A (es) 2018-10-15
US12280106B2 (en) 2025-04-22
KR20220008945A (ko) 2022-01-21
US20190216920A1 (en) 2019-07-18
CN104602706A (zh) 2015-05-06
KR102503316B1 (ko) 2023-02-23
EA030866B1 (ru) 2018-10-31
WO2013142377A2 (en) 2013-09-26
GEP201706650B (en) 2017-03-27
PH12014502085A1 (en) 2014-11-24
WO2013142377A3 (en) 2014-01-23
AR090472A1 (es) 2014-11-12
BR112014023398A2 (pt) 2017-07-11
TN2014000393A1 (en) 2015-12-21
EP2827898B1 (en) 2017-12-20
ECSP14023407A (es) 2015-06-30

Similar Documents

Publication Publication Date Title
PH12018501602A1 (en) Subunit immersion vaccines for fish
PH12018500855A1 (en) Herpes simplex virus vaccine
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
CL2018000432A1 (es) Vacunas terapéuticas contra el hpv18
WO2015052543A3 (en) Malaria vaccination
MX365984B (es) Vectores recombinantes de hvt que expresan antígenos de patógenos de aves y sus usos.
BR112014009565A2 (pt) vírus da doença de marek não patogênico recombinante, ácido nucleico recombinante, vacina, e, método para ajudar na proteção de um frango contra vírus
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
MX2017008504A (es) Vacuna para enfermedad de newcastle y de bursitis infecciosa (nd-ibd) en vector de hvt mejorada.
DK3471766T3 (da) Rekombinante, ikke-patogene mareks sygdomsviruskonstrukter, der koder for infektiøs laryngotracheitisvirus- og infektiøs bursitis virus-antigener patentkrav
PE20190121A1 (es) Virus atenuados de bronquitis infecciosa
CR20140432A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con el
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
CO6700818A2 (es) Vectores de parapoxvirus
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
MX2022001430A (es) Formulaciones de vacuna contra chikungu?a.
EP3826672A4 (en) VACCINE AGAINST THE ZIKA VIRUS
ES2401904R1 (es) Vectores recombinantes basados en el virus modificado de ankara (mva), con delecion en el gen c6l, como vacunas contra el vih/sida y otras enfermedades.
PE20160940A1 (es) Newcastle recombinante expresando las proteinas s del virus de bronquitis aviar y sus aplicaciones
PE20212213A1 (es) Cepas de vbi y usos de las mismas
UA88693U (uk) Штам вірусу інфекційного панкреатичного некрозу ізолят "карпати" (ipnv "karpaty") для отримання вакцини проти інфекційного некрозу підшлункової залози лососевих
TH148817B (th) รีคอมบิแนนท์ไวรัสเริมของนกชนิดมัลติวาเลนต์ และวัคซีนเพื่อสร้างภูมิคุ้มกันสำหรับสปีชีส์ของนก
TH148817A (th) รีคอมบิแนนท์ไวรัสเริมของนกชนิดมัลติวาเลนต์และวัคซีนเพื่อสร้างภูมิคุ้มกันสำหรับสปีชีส์ของนก
TN2010000479A1 (en) Inactivated live - attenuated bluetongue virus vaccine